Centivax

Centivax, Inc. is a comprehensive immunology company that utilizes its proprietary computational immune engineering platform to develop vaccines and therapies for comprehensive protection against a wide range of different targets. Its leading influenza vaccine candidate in clinical trials—previously featured in The New Yorker, the Netflix documentary "Pandemic: How to Prevent an Outbreak," and other media—targets the over $7 billion global influenza market. Follow-up projects also cover Alzheimer's disease, oncology, malaria, and a universal antivenom. This expanding portfolio highlights the platform’s potential not only across a broad spectrum of infectious diseases (including viral, bacterial, protozoan, fungal, parasitic, and bioterror threats) but also in reducing long-term health consequences caused by infections, such as neurodegenerative diseases, cancer, cardiovascular diseases, and autoimmune disorders.